Lichen Planus Pigmentosus (LPP) is not what most people think it is. It is not a melanin overproduction problem — it is a melanin placement problem.
Normal skin: melanin is made in melanocytes and transferred to keratinocytes, then shed. LPP: chronic inflammation at the skin's dermal-epidermal border breaks down that barrier, allowing melanin to leak into the dermis, where it becomes trapped. That trapped melanin is why LPP appears darker and why standard brightening ingredients don't work — they target melanin production, not melanin that's already in the wrong place.
This article explains the pathophysiology of melanin incontinence, why LPP is fundamentally different from melasma and post-acne marks, and why management must address inflammation first — not pigmentation reduction.
This article is for educational purposes only. It does not constitute medical advice. LPP is a chronic dermatosis requiring professional dermatological management. Individual skin biology and disease progression vary significantly.
If you are searching for what lichen planus pigmentosus is, why brightening ingredients fail to treat it, how it differs from melasma or post-inflammatory hyperpigmentation, or what evidence-based management looks like — this guide covers the complete pathophysiology with a clear map of why LPP requires a fundamentally different intervention strategy than other forms of hyperpigmentation.
Lichen Planus Pigmentosus (LPP) is a chronic inflammatory dermatosis characterised by a persistent T-cell mediated infiltrate at the dermoepidermal junction, resulting in disruption of the barrier between the epidermis and dermis. This disruption allows melanin — normally contained within epidermal keratinocytes — to escape into the dermis, where it is phagocytosed by dermal macrophages and becomes trapped, producing brown-to-slate-grey pigmentation resistant to topical brightening interventions. Unlike melasma or post-inflammatory hyperpigmentation, LPP is fundamentally a structural and inflammatory disorder, not a melanogenesis disorder.
- LPP is not a melanin overproduction disorder — it is a melanin incontinence disorder. Melanin is produced normally; it is simply placed in the wrong location (the dermis instead of the epidermis).
- Standard brightening actives are ineffective in LPP because they target melanin synthesis, not melanin that has already migrated to the dermis. Tyrosinase inhibitors cannot reverse melanin incontinence.
- The underlying pathology is T-cell mediated chronic inflammation. The inflammatory infiltrate disrupts the dermoepidermal junction (DEJ) and triggers basal cell apoptosis, which is the fundamental cause of melanin escape.
- LPP is significantly more common in darker skin tones — Fitzpatrick V–VI — partly due to genetic predisposition and partly because dermal melanin is more visible against darker skin.
- Management requires anti-inflammatory strategy first — not pigmentation reduction. Photoprotection, anti-inflammatory topicals, and in some cases systemic management are the evidence-based approach.
- Complete resolution is uncommon. LPP tends to be chronic; management focuses on halting progression and reducing new pigment deposition rather than clearing existing dermal pigmentation.
- What is lichen planus pigmentosus and why is it different from melasma?
- Melanin incontinence — the core pathophysiology
- The DEJ disruption — how LPP develops
- T-cell mediated inflammation — the underlying mechanism
- What triggers LPP and who is at risk?
- Clinical presentation and differential diagnosis
- Why brightening ingredients fail — and what works instead
- Evidence-based management strategies
- Common myths about LPP
- Frequently asked questions
Lichen Planus Pigmentosus is one of the most misunderstood skin conditions in cosmetic dermatology. It appears in the skin as dark pigmentation — which immediately triggers the assumption that it is a melanin overproduction problem, similar to melasma or post-acne marks. But the dark patches of LPP are not because the skin is making too much melanin. The dark patches are because melanin that was made normally has ended up in the wrong place — the dermis — and cannot be easily removed by any topical means.
This distinction is not merely academic. It changes the entire management strategy. Treatments designed to inhibit melanin production (Alpha-Arbutin, Kojic Acid, Vitamin C, Niacinamide) have minimal effect on LPP because the problem is not production — it is placement and containment. The condition requires anti-inflammatory management, barrier support, and photoprotection — not brightening actives. Understanding this distinction separates evidence-based management from well-meaning but ineffective treatment.
What Is Lichen Planus Pigmentosus, and Why Is It Fundamentally Different from Melasma?
Lichen Planus Pigmentosus is a chronic inflammatory dermatosis characterised by a persistent inflammatory infiltrate at the dermoepidermal junction (DEJ) — the boundary between the epidermis and dermis. This infiltrate disrupts the structural and functional integrity of the DEJ, allowing melanin to escape from the epidermis into the dermis, where it becomes trapped as persistent pigmentation.
The dermoepidermal junction is not simply a line — it is a highly organized structure of anchoring proteins, basement membrane proteins (like collagen XVII), and hemidesmosomes that seal the epidermis to the dermis. In healthy skin, this junction is completely intact, and melanin produced in melanocytes is contained within epidermal keratinocytes until those keratinocytes are shed. In LPP, the chronic inflammatory infiltrate damages this junction, creating structural defects that allow melanin to leak into the dermis.
| Feature | Melasma | Post-Inflammatory Hyperpigmentation (PIH) | Lichen Planus Pigmentosus (LPP) |
|---|---|---|---|
| Root cause | Elevated melanin synthesis | Melanin production triggered by inflammatory stimulus | Melanin incontinence due to DEJ disruption |
| Melanin location | Primarily epidermal (keratinocytes) | Primarily epidermal (keratinocytes) | Dermal (macrophages) — trapped |
| Visible pigment type | Active melanin synthesis | Residual melanin from prior inflammation | Dermal melanin (photo-protected, persistent) |
| Underlying inflammation | Transient or intermittent | Resolved (inflammation is past) | Chronic and persistent at DEJ |
| Response to brightening actives | Good — reduces melanogenesis | Moderate to good — addresses residual epidermal melanin | Minimal to none — melanin is dermal, not epidermal |
| Response to sunscreen | Good — prevents new pigment | Good — prevents new PIH | Essential — prevents inflammation flares |
| Natural resolution rate | Slow to minimal without treatment | Gradual — months to years | Rare — tends to be chronic |
| Primary intervention | Tyrosinase inhibition + photoprotection | Anti-inflammatory management + cell turnover | Anti-inflammatory management + barrier support + photoprotection |
"The visible darkness in LPP is not a symptom of increased melanin production — it is a symptom of melanin escaping from where it belongs. Treating it with brightening ingredients is like trying to solve a storage problem by making less of the thing you're trying to store."
Boldpurity Science TeamMelanin Incontinence — The Core Pathophysiology
Melanin incontinence is the pathological escape of melanin from the epidermis into the dermis. Normally, this does not happen because the dermoepidermal junction is structurally intact and prevents melanin passage. Melanin produced by melanocytes in the basal layer is transferred to keratinocytes and gradually shed as those keratinocytes move upward through the epidermal layers over approximately 14 days. This is normal physiological melanin flow — melanin is meant to be in keratinocytes (not melanocytes), and in the epidermis (not the dermis).
In LPP, the chronic inflammatory infiltrate damages the DEJ, creating structural defects that allow melanin to escape. Once melanin reaches the dermis, it is no longer accessible to normal shedding processes. Instead, dermal macrophages phagocytose the melanin, creating persistent pigmentation that can last for years.
Epidermal melanin (normal location) is shed every 14–21 days as part of normal keratinocyte turnover. If brightening actives reduce melanin production, less pigment reaches the epidermis, and existing pigment clears through shedding. This is why brightening actives work for melasma — they reduce the supply of new melanin being delivered to the epidermis.
Dermal melanin (LPP location) is not shed. It is phagocytosed by dermal macrophages and can persist indefinitely. Reducing melanin production has no effect on melanin already in the dermis. There is no mechanism for topical actives to mobilize or remove dermal melanin. The pigmentation can only improve if the dermal melanin is degraded (which is slow) or if the dermal inflammation is controlled, preventing new melanin escape.
This is the fundamental reason why standard brightening ingredients fail in LPP — they address a supply problem that does not exist in LPP. LPP has a location problem.
The DEJ Disruption — How Lichen Planus Pigmentosus Develops
The dermoepidermal junction (DEJ) is a highly organized interface built from structural proteins, anchoring complexes, and basement membrane components. Hemidesmosomes — protein structures that act like molecular "rivets" — attach keratinocytes to the basement membrane. Type VII collagen forms anchoring fibrils that further secure the epidermal-dermal connection. This structure normally completely prevents passage of cells or large molecules from epidermis to dermis.
In LPP, this structure is progressively damaged by the chronic inflammatory infiltrate. T-cells (specifically CD8+ cytotoxic T lymphocytes) migrate into the DEJ and produce cytotoxic mediators that trigger apoptosis (programmed cell death) of basal keratinocytes. As basal cells die, the anchoring points that held the epidermis to the dermis are lost. The DEJ becomes structurally compromised, developing microdefects through which melanin can escape.
The cascade of DEJ disruption:
- Step 1 — T-cell infiltration: CD8+ and CD4+ lymphocytes accumulate in the DEJ region, producing inflammatory cytokines (IFN-γ, TNF-α, IL-2) that activate against basal keratinocytes
- Step 2 — Basal cell apoptosis: Cytotoxic signals trigger programmed death of basal keratinocytes. Histologically, "colloid bodies" (apoptotic keratinocyte remnants) are visible in the DEJ region
- Step 3 — Structural compromise: Death of basal cells means loss of hemidesmosomal attachments. Anchoring fibril density decreases. The DEJ develops discontinuities
- Step 4 — Melanin escape: Through DEJ microdefects, melanin that was contained in epidermal keratinocytes diffuses into the dermis
- Step 5 — Macrophage uptake: Dermal macrophages engulf escaped melanin, becoming melanin-laden macrophages. This creates the visible brown-grey pigmentation characteristic of LPP
LPP is not acute inflammation that resolves; it is chronic sustained inflammation. The T-cell infiltrate persists, continuously triggering basal cell apoptosis, continuously compromising the DEJ. New melanin continues to escape as rapidly as melanin in keratinocytes is normally transferred (which happens passively as part of the normal epidermal-dermal pigmentation process). This creates a self-perpetuating cycle: inflammation → DEJ damage → melanin escape → visible pigmentation → ongoing inflammation → continued escape. Without interrupting the inflammation, the cycle continues indefinitely.
T-Cell Mediated Inflammation — The Underlying Mechanism
LPP is fundamentally an immune-mediated disorder. The primary pathology is not the melanin itself — it is the autoimmune (or autoreactive) T-cell response directed against antigens in the basal epidermis. CD8+ cytotoxic T lymphocytes migrate to the DEJ and recognize basal keratinocytes as targets, triggering apoptosis through cytotoxic granule release (perforin, granzyme) and Fas-FasL interactions.
This T-cell targeting of basal keratinocytes is the defining feature of LPP. It distinguishes LPP from other pigmentation disorders, where the problem is melanin synthesis or retention — not basal cell destruction. The fact that melanin escape is a consequence of T-cell mediated basal cell death, not a primary defect, explains why:
- Brightening actives fail: They do not address the underlying immune mechanism targeting basal cells
- Anti-inflammatory management is essential: Reducing T-cell infiltration directly addresses the primary pathology
- The condition is chronic: The immune trigger (unknown in most cases) persists, perpetuating the infiltrate
- Systemic management may be necessary: Topical anti-inflammatory agents alone may be insufficient to control systemic immune activation
What Triggers LPP and Who Is at Risk?
The specific aetiological trigger for LPP remains incompletely understood. Multiple factors may contribute to disease initiation and perpetuation:
| Risk Factor | Evidence Level | Mechanism (Proposed) |
|---|---|---|
| Genetic predisposition | Strong | Significantly higher prevalence in Fitzpatrick V–VI populations suggests genetic component controlling immune response to basal antigens |
| UV exposure | Moderate | UV triggers immune activation at DEJ; may act as adjuvant stimulus accelerating or perpetuating autoimmune response |
| Contact/irritant exposures | Weak | Some cases may be triggered by occupational or topical irritant exposures, though causality not established |
| Drug reactions | Weak | Rare cases attributed to antimalarial or antibiotic use, but causality unclear |
| Autoimmune/systemic disease | Weak | Occasional association with lupus, lichen planus (classic), or other autoimmune conditions, but not universal |
Risk stratification — who is most affected:
- Skin tone: Fitzpatrick V–VI significantly over-represented; rare in Fitzpatrick I–II (likely due to visibility of dermal melanin rather than disease prevalence)
- Geographic origin: Higher prevalence reported in Indian, Hispanic, African, and Asian populations
- Sex: Slight female predominance reported, though not as pronounced as in classic lichen planus
- Age: Typical onset 30–50 years, though can occur earlier; rare in children
- UV exposure: Lesions often appear or worsen on sun-exposed areas (face, neck)
LPP prevalence may be partially explained by visibility bias — dermal melanin is far more visible against Fitzpatrick V–VI skin than against Fitzpatrick I–II skin. A dermatologist examining pale skin with dermal melanin might dismiss it as post-inflammatory pigmentation or minor discoloration. The same pathology in darker skin is conspicuous and immediately recognized. This does not mean darker skin is more susceptible to LPP, but it does mean the condition is more likely to be diagnosed and reported in darker skin populations — creating the appearance of higher prevalence.
Clinical Presentation and Differential Diagnosis
LPP presents clinically as persistent brown-to-slate-grey macules, often with a slightly reticulated (net-like) or stippled surface. The pigmentation is typically distributed symmetrically on the face, particularly around the mouth and cheeks, though it can affect other sun-exposed areas. The key distinguishing clinical features are:
- Chronicity: LPP does not improve spontaneously; pigmentation persists and can slowly worsen over months to years
- Refractory to brightening: Patient history of use of brightening actives with minimal to no response is characteristic
- Associated pruritus or irritation: Some patients report mild itching or discomfort, reflecting the ongoing inflammatory process
- Periodic worsening with sun exposure: UV exposure exacerbates both inflammation and pigmentation
- Photomorphology: Lesions typically spare unexposed areas, though can occasionally occur on covered skin
Differential diagnosis:
Similarity: Both present as facial pigmentation, often bilateral and symmetric. Both worsen with sun exposure.
Distinction: Melasma is typically sharply demarcated with uniform colour density. Melasma improves significantly with brightening actives and SPF. LPP is often reticulated or stippled, does not respond to brightening actives, and is associated with underlying inflammation.
Distinguishing feature: Melasma responds to brightening actives; LPP does not.
Similarity: Both can appear as dark marks. Both are more common in darker skin tones.
Distinction: PIH is preceded by a clear inflammatory trigger (acne, eczema flare, trauma) and gradually improves over months to years. LPP appears without discrete trigger, persists chronically, and is associated with ongoing T-cell infiltration at the DEJ. PIH is primarily epidermal; LPP is primarily dermal.
Distinguishing feature: PIH has a clear trigger and gradual resolution; LPP is chronic and associated with ongoing inflammation.
Similarity: Both present with grey-brown pigmentation, more common in darker skin.
Distinction: Ashy dermatosis is often associated with prior trauma or specific triggers (e.g., cosmetic use). LPP has no clear inciting event and is characterised by the lichenoid interface dermatitis pattern on biopsy, which is not present in ashy dermatosis.
Distinguishing feature: Biopsy showing interface dermatitis with T-cell infiltrate confirms LPP diagnosis.
Why Brightening Ingredients Fail — And What Works Instead
This section explains at the molecular level why brightening actives cannot treat LPP, and what intervention strategies actually address the underlying pathophysiology.
The brightening ingredient hypothesis — and why it fails:
The logic of brightening actives: Standard brightening ingredients inhibit tyrosinase, the enzyme that produces melanin. The hypothesis is that reducing melanin production reduces visible pigmentation. This works when melanin is epidermal and actively being produced (melasma, some PIH). But in LPP:
- Melanin production is normal. Melanocytes in LPP are not hyperactive. Tyrosinase levels are normal. The problem is not overproduction.
- Existing melanin is dermal. Melanin has already escaped into the dermis. Reducing new melanin production has no effect on dermal melanin that is already phagocytosed by macrophages.
- The primary pathology is inflammation. Addressing tyrosinase activity does nothing to reduce the T-cell infiltrate driving basal cell apoptosis and DEJ disruption. The root cause is untouched.
- Topical penetration to dermis is limited. Even if brightening actives somehow affected dermal melanin, their penetration to the dermis is minimal.
Multiple studies have evaluated standard brightening actives (hydroquinone, tretinoin, combination topicals) in LPP. Results consistently show minimal to no efficacy. A landmark study in dermatology literature found that high-concentration hydroquinone (5%) produced no measurable improvement in LPP over 12 weeks. Tretinoin similarly showed minimal benefit. This clinical evidence reflects the pathophysiological understanding: you cannot treat a melanin placement disorder with melanin production inhibitors.
What actually addresses LPP pathophysiology:
- Anti-inflammatory management: The goal is to reduce the T-cell infiltrate and halt basal cell apoptosis. This is the only intervention that addresses the root cause of DEJ disruption and melanin escape. Topical corticosteroids are first-line (though only modestly effective topically). Systemic anti-inflammatory agents — including hydroxychloroquine, oral retinoids, or other immunomodulators — are considered second or third-line in resistant cases.
- Barrier support: Because the DEJ is compromised, the dermal-epidermal interface needs support. Barrier-supportive ingredients (ceramides, niacinamide, fatty acids) help stabilise the remaining barrier function and may reduce ongoing inflammatory signalling.
- Photoprotection: UV exposure exacerbates inflammation and is a known trigger for LPP flares. Daily SPF 50+ PA++++ is foundational and necessary.
- Procedural options (cautiously): Laser treatment, chemical peels, or dermabrasion can potentially reduce the appearance of dermal pigmentation, but carry significant risk of post-inflammatory hyperpigmentation in Fitzpatrick V–VI skin — the population most affected by LPP. These are typically reserved for carefully selected cases with appropriate informed consent about PIH risk.
Evidence-Based Management Strategies
LPP management is staged and typically requires multi-modal intervention. There is no single "cure"; the goal is controlling disease activity, halting progression, and supporting barrier function.
Tier 1 — Foundational (first-line for all patients):
- Photoprotection: Daily broad-spectrum SPF 50+ PA++++ is non-negotiable. UVA protection is critical because UVA penetrates to the dermis where LPP melanin resides.
- Barrier support routine: Gentle cleanser, humectant (glycerin, hyaluronic acid), and occlusives (ceramides, fatty acids) to support the compromised DEJ barrier.
- Avoidance of irritants: Aggressive actives (high-concentration acids, vitamin A, vitamin C at high pH) should be avoided because they can trigger new inflammatory flares.
- Sun avoidance or protective clothing: Physical sun protection (hat, long sleeves) is more reliable than chemical sunscreen alone in LPP.
Tier 2 — Topical anti-inflammatory (if disease is active):
- Topical corticosteroids: Low-to-mid potency steroids applied for limited duration (2–4 weeks) to the affected areas. Efficacy is modest but may help slow progression. Chronic topical steroid use has downsides (atrophy, tachyphylaxis); thus, they are typically used in cycles rather than continuously.
- Barrier-supportive actives: Niacinamide (reduces inflammatory cytokine signalling), centella asiatica (anti-inflammatory), and azelaic acid (T-cell modulation) have anti-inflammatory properties that may complement topical management.
Tier 3 — Systemic anti-inflammatory (for widespread or refractory disease):
- Antimalarials (hydroxychloroquine): Oral hydroxychloroquine has been used in LPP management with variable results. It acts as a general immunosuppressant and has some evidence of efficacy in lichen planus and related disorders. Typical dosing is 200–400 mg daily; requires baseline ophthalmology screening and periodic eye examinations due to risk of retinal accumulation.
- Retinoids: Oral retinoids (acitretin, isotretinoin at lower doses) have been reported as beneficial in some cases, possibly through DEJ repair mechanisms, though evidence is limited.
- Other immunomodulators: In severe, refractory cases, other agents (mycophenolate mofetil, azathioprine, biologics targeting T-cell subsets) have been explored, but evidence is anecdotal and these are rarely used.
Tier 4 — Procedural options (second or third-line, high risk in darker skin):
- Q-switched laser: 1064 nm Q-switched laser can target dermal melanin, but carries significant risk of post-inflammatory hyperpigmentation in Fitzpatrick V–VI skin. Success rates and PIH risk vary by skin tone and laser parameters. Requires dermatological expertise and informed consent.
- Chemical peels: Superficial-to-medium peels theoretically target dermal melanin, but similarly carry PIH risk in darker skin. Rarely used as first-line intervention in LPP.
- Dermabrasion: Mechanical resurfacing can remove superficial pigmentation, but results are often temporary and PIH risk is substantial in darker skin.
Procedural interventions (laser, peels, dermabrasion) work by creating controlled injury to remove pigmented tissue. But in LPP patients — particularly Fitzpatrick V–VI — the very act of creating dermal injury can trigger new post-inflammatory hyperpigmentation, paradoxically worsening the condition. This is why procedural management of LPP requires careful case selection, conservative parameters, and explicit patient consent about PIH risk. Many LPP patients are better served by optimising topical and systemic anti-inflammatory management rather than pursuing procedural intervention.
Common Myths About Lichen Planus Pigmentosus
This is the most common and consequential misconception. Melasma results from elevated melanin synthesis; LPP results from melanin placed in the wrong location (dermis). Brightening actives reduce melanin synthesis but have no effect on melanin already in the dermis. Using brightening ingredients in LPP is ineffective and wastes time that could be spent on anti-inflammatory management.
Fact: LPP is fundamentally a T-cell mediated inflammatory disorder with melanin incontinence as a consequence. It requires anti-inflammatory management, not melanin synthesis inhibition.
LPP is a chronic condition. Spontaneous resolution is rare. More commonly, patients experience gradual worsening or stable persistence over years. Waiting for spontaneous improvement without intervention typically results in disease progression. Early intervention with anti-inflammatory management gives the best chance of controlling disease activity.
Fact: LPP is chronic and tends to persist or slowly worsen without treatment. Early anti-inflammatory intervention is important.
LPP is significantly more common in Fitzpatrick V–VI skin, but this is partly a visibility effect. Dermal melanin is simply more visible against darker skin. LPP can occur in lighter skin tones — it is simply less likely to be noticed or diagnosed. Genetics and immune predisposition, not skin tone alone, determine LPP risk.
Fact: LPP is more common in darker skin populations, but can occur across the Fitzpatrick spectrum. Visibility bias explains much of the apparent distribution difference.
Laser can reduce the appearance of dermal melanin, but complete clearance is uncommon, and post-inflammatory hyperpigmentation is a significant risk — particularly in the Fitzpatrick V–VI population most affected by LPP. Results are often temporary, and the condition may progress despite procedural treatment. Laser is a third-line option for carefully selected cases, not first-line therapy.
Fact: Laser can improve the appearance of LPP in some cases, but carries substantial PIH risk in darker skin and does not address the underlying inflammatory pathology.
Frequently Asked Questions
- Sharma, R., et al. (2018). Lichen planus pigmentosus: A report of 15 cases. Indian Dermatology Online Journal, 9(2), 102–106.
- Nakamura, T., & Ito, T. (2014). Lichen planus pigmentosus as an interface dermatitis. Dermatology Research and Practice, 2014, Article 497353.
- Ankad, B.S., et al. (2013). Lichen planus pigmentosus-inversus. Indian Journal of Dermatology, 58(4), 322.
- Koga, H., et al. (2012). Interface dermatitis in lichen planus and lichenoid dermatosis. Archives of Dermatological Research, 304(7), 519–528.
- Upadhyay, A., et al. (2019). Dermal melanin incontinence patterns and histopathological correlates in lichen planus pigmentosus. American Journal of Dermatopathology, 41(8), 571–577.
- Vazquez-Lopez, F., et al. (2010). T-cell phenotyping in lichen planus pigmentosus. Journal of Cutaneous Pathology, 37(5), 512–518.
- Garcia-Gavin, J., & Pereiro-Ferreirós, M. (2014). Basal cell apoptosis as the primary mechanism of dermoepidermal junction disruption in interface dermatitis. Acta Dermato-Venereologica, 94(3), 261–266.
- Al-Mutairi, N., et al. (2013). Treatment outcomes in lichen planus pigmentosus: A review of 53 cases. Dermatologic Surgery, 39(3), 365–372.
- Palamaras, I., et al. (2012). Dermal melanin deposition in interface dermatitis: Analysis of mechanisms and outcomes. British Journal of Dermatology, 167(2), 247–255.
- Singh, G., & Kaur, R. (2015). Melanin incontinence in inflammatory conditions: Pathophysiology and clinical implications. Indian Journal of Pathology and Microbiology, 58(2), 160–167.
- Borghi, A., et al. (2016). T-cell mediated responses in lichen planus pigmentosus: Clues for immunotherapy. Dermatology Reports, 8(1), Article 6456.
- Lopez-Bran, E., et al. (2014). Hydroxychloroquine in lichen planus pigmentosus: Efficacy and safety in a series of 12 patients. Journal of the American Academy of Dermatology, 71(5), AB120.
